The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental ...

Discover the 10 best Infrastructure as Code (IaC) tools for DevOps teams in 2025. Learn how these tools enhance automation, stability, and scalability in cloud environments. Improve your deployment ...

Stop wasting time on generic gifts nobody remembers. Learn how to make DIY Christmas presents that are fast, simple, and guaranteed to impress. These ideas work for family, friends, or even ...

Buying medicines can get confusing because the same tablet or syrup is often sold under different names and prices. Medicines come in two main forms: branded drugs and generic drugs. A branded drug is ...

The generic product is now available nationwide in strengths of 0.3mg, 0.45mg, 0.625mg, 0.9mg, and 1.25mg. The Food and Drug Administration (FDA) has approved the first generic version of Premarin ® ...

The US Food and Drug Administration will take steps to streamline the development of generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to accelerate ...

Jamie Dimon is right to be alarmed about our national-security vulnerabilities, especially an overreliance on China and India for generic prescription drugs (“Investments for National Security,” op-ed ...

Big pharmaceutical companies are boosting their production capacity of branded medications with billions of dollars in new U.S. manufacturing plant construction, but generic drug production still ...

The U.S. Food and Drug Administration has introduced a new pilot program aimed at accelerating the review process for generic drugs that are both tested and produced entirely within the United States.

Oct 3 (Reuters) - The U.S. Food and Drug Administration said on Friday it has launched a new pilot program to speed up the review process for generic drugs that are tested and manufactured entirely in ...

Against a backdrop of tariff updates and a drug pricing deal from the Trump administration, the FDA charted a pair of moves this week in its push to make drug manufacturing more attractive in the U.S.